Diabetes, obesity & metabolism · 2025
Feasibility study of a combined insulin-delivery and glucose sensor system worn over 7 days in persons with type 1 diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cunningham Hannah, Apostolopoulos John, Ngan Jennifer, Jones Hanna, Barnard-Kelly Katharine, Brown Katrin, Dutt-Ballerstadt Ralph, Flint Steve, Kong Yee Wen, Netzer Emma, Obeyesekere Varuni, Reid Solomon, Wu Huan-Ping, Seidl Thomas, O'Neal David
Аннотация
AIMS: We aimed to evaluate sensor accuracy and insulin delivery integrity of a novel device combining continuous glucose monitoring (CGM) with an insulin delivering cannula (CGM-IS) (Pacific Diabetes Technologies, Portland, Oregon, USA) during 7-day wear, in adults with type 1 diabetes (T1D).
MATERIALS AND METHODS: This single centre, single arm, non-randomised study involves 40 T1D adults who were using insulin pumps and CGM for 7 days, with three meal test days and four free living days. The main endpoints were sensor accuracy according to mean average relative difference (MARD) and infusion set function reflected by time in range (TIR), mean sensor glucose and total daily dose (TDD) of insulin.
RESULTS: Sensor MARD was 16.4%, 14.8% and 17.7% on Days 1, 4 and 7, respectively. 60.0% of readings met the 15/15 criterion for blood glucose (BG) readings <70.2 mg/dL. Insulin delivery integrity was maintained to Day 3. At Days 5-6 TDD increased by 7.3 units/day (16%), mean BG increased by 16.2 mg/dL (10.2%), and TIR fell by -7.8% (11.2%). 92.1% of devices lasted >4 days. Mean wear time was 6.3 ± 1.4 days. The device was well tolerated.
CONCLUSION: This human feasibility study supports the potential of CGM-IS use for up to 7 days with a mean survival of over 6 days. However, our data indicate that the durability of insulin delivery and sensor refinement are required prior to commercialisation.
MATERIALS AND METHODS: This single centre, single arm, non-randomised study involves 40 T1D adults who were using insulin pumps and CGM for 7 days, with three meal test days and four free living days. The main endpoints were sensor accuracy according to mean average relative difference (MARD) and infusion set function reflected by time in range (TIR), mean sensor glucose and total daily dose (TDD) of insulin.
RESULTS: Sensor MARD was 16.4%, 14.8% and 17.7% on Days 1, 4 and 7, respectively. 60.0% of readings met the 15/15 criterion for blood glucose (BG) readings <70.2 mg/dL. Insulin delivery integrity was maintained to Day 3. At Days 5-6 TDD increased by 7.3 units/day (16%), mean BG increased by 16.2 mg/dL (10.2%), and TIR fell by -7.8% (11.2%). 92.1% of devices lasted >4 days. Mean wear time was 6.3 ± 1.4 days. The device was well tolerated.
CONCLUSION: This human feasibility study supports the potential of CGM-IS use for up to 7 days with a mean survival of over 6 days. However, our data indicate that the durability of insulin delivery and sensor refinement are required prior to commercialisation.